12:00 AM
Oct 12, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Celvapan regulatory update

The EC approved Baxter's Celvapan H1N1 pandemic influenza vaccine. The dosing schedule consists of two 7.5 µg doses given 21 days apart. Earlier this month, EMEA's CHMP issued a positive opinion to grant marketing approval for...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >